Abstracts tagged "Gout and uric acid"

Abstract Number: 1221 • 2014 ACR/ARHP Annual Meeting
Serum Uric Acid As an Independent Risk Factor on Progression of Chronic Kidney Disease in Gout Patients with Uric Acid Lowering Agent
Young Hyup Lim¹, Eun-Jung Park¹, Seulkee Lee², Hemin Jeong³, Hyungjin Kim⁴, Jinseok Kim¹, Jaejoon Lee⁵, Hoon-Suk Cha³ and Eun-Mi Koh⁶, ¹Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ²Internal Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Internal Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seul, South Korea, ⁵Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose Hyperuricemia is particularly common in patients with chronic kidney disease (CKD). Its role, however, as a risk factor for renal outcomes of CKD is…
Abstract Number: 1217 • 2014 ACR/ARHP Annual Meeting
The Random Urine Uric Acid to Creatinine Ratio As a Predictor of 24-Hour Urine Uric Acid Excretion in Gout Patients
Sang Tae Choi¹, Jung-Soo Song² and Eun-Hye Park², ¹Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea, ²Chung-Ang University College of Medicine, Seoul, South Korea
Background/Purpose: Gout is an inflammatory disease resulted from an increased body pool of uric acid. The measurement of 24-hour uric acid excretion is important to…
Abstract Number: 830 • 2014 ACR/ARHP Annual Meeting
Profound Hypouricemia Induced in Human Subjects By Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1
Raymond P. Warrell Jr.¹, Anna Klukovits², Keith Barnes³, Chitkala Satyanarayana⁴, Chris Cheeseman⁵ and John Piwinski¹, ¹Relburn-Metabolomics, Inc., Westfield, NJ, ²SOLVO Biotechnology, Budapest, Hungary, ³AMRI, Albany, NY, ⁴AMRI, Singapore, Singapore, ⁵University of Alberta, Alberta, AB, Canada
Background/Purpose: A prototype anticancer drug (RLBN1001) induced marked hypouricemia in studies of > 350 human subjects. Preliminary exploration suggested dual effects on uric acid (UA)…
Abstract Number: 828 • 2014 ACR/ARHP Annual Meeting
Extent of Urate Deposition in Asymptomatic Hyperuricemia and Symptomatic Gout: A Dual Energy Computed Tomography Study
Nicola Dalbeth¹, Meaghan House¹, Opetaia Aati¹, Paul Tan², Christopher Franklin², Anne Horne¹, Gregory Gamble¹, Lisa K. Stamp³, Anthony Doyle² and Fiona M. McQueen⁴, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
Background/Purpose: Recent studies have reported that ultrasound features of urate crystal deposition are present in some asymptomatic individuals with hyperuricemia, suggesting that subclinical urate deposition…
Abstract Number: 178 • 2014 ACR/ARHP Annual Meeting
The Effect of Initiating Pharmacologic Insulin on Serum Uric Acid Levels in Patients with Diabetes
Lindsey MacFarlane¹, Chih-Chin Liu² and Daniel H. Solomon³, ¹Medicine, Brigham and Women's Hospital, Boston, MA, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose Substantial evidence links gout and hyperuricemia to diabetes. Previous studies report an association between increasing uric acid (UA) levels, insulin resistance, and type 2…
Abstract Number: 168 • 2014 ACR/ARHP Annual Meeting
Positive Association Between Tomato Consumption and Serum Urate: Investigating an Anecdotal Trigger of Gout Flares
Tony R. Merriman¹, Nicola Dalbeth², Peter B. B. Jones³, Lisa K. Stamp⁴, Murray Cadzow⁵, Ruth Topless¹ and Tanya Flynn⁵, ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Medicine, Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, ⁴Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Otago, Dunedin, New Zealand
Background/Purpose: Gout is characterised by intermittent flares of inflammation in response to monosodium urate crystals in the joints. Gout flares can be triggered by dietary…
Abstract Number: L10 • 2014 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Two Phase III Clinical Trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2)
Kenneth G. Saag¹, Scott Adler², Nihar Bhakta³, Maple Fung³, Jeff Kopicko³, Chris Storgard³ and Thomas Bardin⁴, ¹Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ²AstraZeneca Pharmaceuticals, Wilmington, DE, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France
Background/Purpose: Inadequate response to allopurinol monotherapy is common. Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout in…
Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Nicola Dalbeth¹, Meaghan House², Gregory Gamble², Bregina Pool¹, Anne Horne², Lauren Purvis², Angela Stewart², Marilyn E. Merriman³, Murray Cadzow⁴, Amanda Phipps-Green³ and Tony R. Merriman³, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…
Abstract Number: 2009 • 2013 ACR/ARHP Annual Meeting
Outcome Of Allopurinol Or Febuxostat Treatment In Gout Patients Naïve To Urate-Lowering Therapy
Puja Khanna¹, Hind Hatoum^2,3, Swu-Jane Lin^2,4, Aki Shiozawa⁵, Kasem Akhras⁶ and Dinesh Khanna¹, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Hind T. Hatoum and Company, Chicago, IL, ³University of Illinois at Chicago, chicago, IL, ⁴University of Illinois at Chicago, Chicago, IL, ⁵Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁶Global Outcomes Research, Formerly of Takeda Pharmaceuticals International, Inc, Deerfield, IL
Background/Purpose: In the US, 3.9% (8.3 million) of the population have self-reported gout, and 21.4% (43.3 million) have hyperuricemia. The 2012 ACR guidelines recommend febuxostat…
Abstract Number: 2002 • 2013 ACR/ARHP Annual Meeting
Prophylactic Duration and Serum Uric Acid Level Are Associated With Gout Flare During Urate Lowering Treatment
Hyo-Jin Choi¹, Chan Hee Lee², Sang Tae Choi³, Jung-Soo Song³, Hyoun-Ah Kim⁴, Chang-Hee Suh⁵, Hoyeon Joo⁶, Ki Chul Shin⁷ and Hanjoo Baek¹, ¹Rheumatology, Gachon University Gil Hospital, Incheon, South Korea, ²Div Rheum Dept of Intl Med, NHIC Ilsan Hospital, Goyang-si, South Korea, ³Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ⁴Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁵Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁷Rheumatology, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: To evaluate the clinical factors on gout flare during urate lowering treatment Methods: We retrospectively examined data derived from 228 patients who had been treated…
Abstract Number: 2003 • 2013 ACR/ARHP Annual Meeting
Outcome Of Gout Patients Placed On Febuxostat After Failing To Reach Serum Urate Target With Allopurinol
Hind Hatoum^1,2, Dinesh Khanna³, Aki Shiozawa⁴, Swu-Jane Lin^1,5, Kasem Akhras⁶ and Puja Khanna⁷, ¹Hind T. Hatoum and Company, Chicago, IL, ²University of Illinois at Chicago, chicago, IL, ³Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁵University of Illinois at Chicago, Chicago, IL, ⁶Global Outcomes Research, Formerly of Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: The 2012 American College of Rheumatology (ACR) gout guidelines recommends allopurinol or febuxostat as first-line urate-lowering therapy (ULT). Purpose of this study was to…
Abstract Number: 2006 • 2013 ACR/ARHP Annual Meeting
Uric Acid Level Is Not An Independent Predictor Of Cardiovascular Diseases In Gout Patients With Treatment; Long-Term Follow-Up Data In Single Tertiary Center In South Korea
Seulkee Lee¹, Eun-Jung Park², Jinseok Kim³, Chan Hong Jeon⁴, Hyungjin Kim⁵, Jaejoon Lee¹, Eun-Mi Koh¹ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ³Internal Medicine, Jeju National University Hospital, Jeju, South Korea, ⁴Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁵Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Hyperuricemia and gout are closely related conditions that are prevalent worldwide. A possible link between hyperuricemia and cardiovascular diseases (CVD) has been a debated…
Abstract Number: 1983 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Birefringent Crystals In Three Inflammation-Prone Tissues
Jane Park¹, Divya Soman², Martine P. Roudier³ and Peter A. Simkin⁴, ¹Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Pathology, University of Washington, Seattle, WA, ⁴Div of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: When serum is hyperuricemic, so too are all interstitial fluids other than CSF and sweat. Anecdotally, urate crystals deposit as grossly visible tophi in…
Abstract Number: 1722 • 2013 ACR/ARHP Annual Meeting
Does Starting Allopurinol Prolong Acute Treated Gout?
Erica Hill¹, Jay B. Higgs², Karen Sky³, Michelle Sit⁴ and Angelique N. Collamer⁵, ¹Rheumatology, San Antonio Military Medical Center, Fort Sam Houston, TX, ²Rheumatology, San Antonio Military Medical Center, JBSA - Fort Sam Houston, TX, ³Rheumatology, US Department of Veterans Affairs, Alaska VA Healthcare System, Anchorage, AK, ⁴Subspecialty Clinic - Rheumatology, David Grant Medical Center, Travis AFB, CA, ⁵Internal Medicine, Langley AFB Hospital, Langley AFB, VA
Background/Purpose: Gout is a common cause of morbidity in the US population. Traditionally, allopurinol is not initiated during an acute episode to avoid prolonging…
Abstract Number: 1902 • 2012 ACR/ARHP Annual Meeting
What Factors Are Associated with Target Serum Urate Concentrations in Patients with Gout?
Nicola Dalbeth¹, Meaghan House², Anne Horne², Keith J. Petrie³, Fiona M. McQueen⁴ and William Taylor⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁵University of Otago, Wellington, New Zealand
Background/Purpose: Long term serum urate (SU) lowering to a target of

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].